DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Ozempic (semaglutide 0.5–2mg) costs $349/month via NovoCare direct cash-pay, $25/month with insurance + savings card, or up to $1,028/month list retail. Updated for 2026.
Same drug, different pricing channels. The spread is often $800-1000/month between cheapest and retail cash.
| Channel | Source | |
|---|---|---|
Cash-pharmacy + savings card Commercially insured with coverage — manufacturer copay card (GoodRx/SingleCare style discount otherwise). | $25 with commercial insurance + savings cardBest value | Manufacturer savings card terms |
With insurance (covered, after PA) Commercial plan that covers the drug after prior authorization — copay depends on your tier. | $25/month – $150/month | Plan formulary copay tiers |
Compounded (telehealth, where legal) Cash-pay via 503A pharmacy telehealth. Not FDA-approved as the brand — regulatory wind-down ongoing. | $199/month | Compounded semaglutide via Hims |
Manufacturer cash — NovoCare direct cash-pay Anyone with a valid prescription who pays cash — no insurance required, valid in all 50 states. | $349/monthLowest | NovoCare |
Retail / list (cash, no programs) Walk-in pharmacy price with no insurance, savings card, or manufacturer program. | $1,028/month listList price | WAC / pharmacy list, LoseLab pricing desk |
Cheapest mfg cash price today is $349/mo. We’ll email you the day it gets cheaper — no spam, unsubscribe anytime.
Ozempic's list price is about $1,028/month — lower than Wegovy's $1,349. NovoCare direct cash-pay reduces this to $349/month for the 0.25, 0.5 and 1 mg doses ($499 for 2 mg). Manufacturer cash-pay is open to anyone with a valid prescription, regardless of insurance status.
Lowest observed cash-pay ranges from our state cost matrix. Where you fill changes the price.
Ozempic is FDA-approved exclusively for type 2 diabetes. T2D-indicated insurance coverage is broad — commercial plans cover Ozempic with PA, typically requiring metformin trial and A1C documentation. Copays range $25–$150/month. Off-label weight-loss prescribing is increasingly audited and denied in 2026.
Two Ozempic programs: (1) Ozempic savings card — as little as $25/month with commercial coverage (maximum savings $100/month); (2) NovoCare direct cash-pay — $349/month for 0.25–1 mg ($499 for 2 mg), no insurance needed. No weight-loss-indicated programs — for weight loss, switch to FDA-approved Wegovy.
Medicare Part D covers Ozempic for T2D — well-established pathway, no special exclusion. PA typically requires metformin trial. Off-label weight-loss prescribing not covered.
Medicaid covers Ozempic for T2D in most states. PA criteria similar to commercial plans (A1C, metformin trial). Weight-loss-only prescribing not covered.
Same semaglutide, dose optimized for weight loss (2.4mg). Better PA approval rate for weight loss because the prescribing matches the FDA indication.
$199/month — same active ingredient, not FDA-approved as Ozempic. Telehealth route, compounded by 503A pharmacy.
Different molecule, superior A1C reduction in SURPASS-2 head-to-head trial. About $1,112/month list; cash-pay from $499/month via TrumpRx/LillyDirect.
Ozempic out-of-pocket cost ranges from $25/month (T2D + covered + savings card) to about $1,028/month (list price). For T2D, coverage is straightforward and the savings card brings copay to $25. For weight loss, Ozempic is the wrong door — switch to Wegovy (NovoCare $349/month direct).
Read full Ozempic review →Pricing verified monthly against current manufacturer and pharmacy formularies. Coverage rules vary by plan — verify against your member portal before prescribing.